Abstract: Provided are, inter alia, compounds having a structure of Formulae (X) to (XVII), or a subordinate structure thereof, composition including the same and methods of use.

Abstract: Provided are, inter alia, compounds having a structure of Formula (X), or a pharmaceutically acceptable salt thereof composition including the same and methods of use. Ring A, L1, L2, W, R2A, R2B, and R10 are as described herein.

Abstract: Methods of preventing disease or treating a subject likely to develop or having a neurodegenerative, degenerative or metabolic disease include administration of nicotinamide dinucleotide (NAD) modulating agents. Compositions include one or more agents which increase or decrease NAD in vivo or in vitro.

Abstract: Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimer's disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia/reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and/or animal models of prion disease, PD and ALS.

Abstract: The invention provides methods for generating and screening agents that are useful for treating, diagnosing and monitoring Parkinson's Disease and other synucleinopathies.

Abstract: A method of screening for compounds that module expression of specific macromolecules, the “target”. The method is particularly useful in that it does not require separation of target-bound and excess ligand and therefore enables, but is not limited to, High Throughput Screening for compounds that increase or decrease the levels or amounts of a target present in a biological sample. The method can also be used for high-throughput diagnosis of a condition leading to an increase or decrease of a cellular macromolecule.

Abstract: A method of screening for compounds that module expression of specific macromolecules, the “target”. The method is particularly useful in that it does not require separation of target-bound and excess ligand and therefore enables, but is not limited to, High Throughput Screening for compounds that increase or decrease the levels or amounts of a target present in a biological sample. The method can also be used for high-throughput diagnosis of a condition leading to an increase or decrease of a cellular macromolecule.

Abstract: A method of screening for compounds that module expression of specific macromolecules, the “target”. The method is particularly useful in that it does not require separation of target-bound and excess ligand and therefore enables, but is not limited to, High Throughput Screening for compounds that increase or decrease the levels or amounts of a target present in a biological sample. The method can also be used for high-throughput diagnosis of a condition leading to an increase or decrease of a cellular macromolecule.

Abstract: The invention concerns a method for screening substances capable of having therapeutic action in the treatment of transmissible subacute spongiform encephalopathy (TSSE) or prion diseases comprising a step of isolating the PrPres, from the spleen, methods for isolating the PrPres, particularly adapted to said screening method and their applications, in particular for detecting PrPres.